Relmada Therapeutics (RLMD) Competitors $2.85 -0.13 (-4.36%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RLMD vs. NLTX, ZIOP, KMDA, QTTB, CYRX, BTMD, ACIU, CMPS, JSPR, and SAGEShould you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include Neoleukin Therapeutics (NLTX), ZIOPHARM Oncology (ZIOP), Kamada (KMDA), Q32 Bio (QTTB), Cryoport (CYRX), biote (BTMD), AC Immune (ACIU), COMPASS Pathways (CMPS), Jasper Therapeutics (JSPR), and Sage Therapeutics (SAGE). Relmada Therapeutics vs. Neoleukin Therapeutics ZIOPHARM Oncology Kamada Q32 Bio Cryoport biote AC Immune COMPASS Pathways Jasper Therapeutics Sage Therapeutics Relmada Therapeutics (NASDAQ:RLMD) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations. Which has more volatility & risk, RLMD or NLTX? Relmada Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Is RLMD or NLTX more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -129.80% -112.06% Neoleukin Therapeutics N/A -37.22%-30.91% Do insiders & institutionals have more ownership in RLMD or NLTX? 45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 18.0% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer RLMD or NLTX? Neoleukin Therapeutics received 33 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 45.87% of users gave Neoleukin Therapeutics an outperform vote while only 41.46% of users gave Relmada Therapeutics an outperform vote. CompanyUnderperformOutperformRelmada TherapeuticsOutperform Votes1741.46% Underperform Votes2458.54% Neoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% Which has stronger earnings & valuation, RLMD or NLTX? Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$98.79M-$2.87-0.99Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-4.93 Does the media prefer RLMD or NLTX? In the previous week, Relmada Therapeutics had 2 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 2 mentions for Relmada Therapeutics and 0 mentions for Neoleukin Therapeutics. Relmada Therapeutics' average media sentiment score of 0.00 equaled Neoleukin Therapeutics'average media sentiment score. Company Overall Sentiment Relmada Therapeutics Neutral Neoleukin Therapeutics Neutral Do analysts prefer RLMD or NLTX? Relmada Therapeutics currently has a consensus price target of $7.50, indicating a potential upside of 163.16%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Relmada Therapeutics is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryRelmada Therapeutics and Neoleukin Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLMD vs. The Competition Export to ExcelMetricRelmada TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.98M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.994.8587.8613.46Price / SalesN/A374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book1.8010.216.946.30Net Income-$98.79M$153.61M$119.12M$225.93M7 Day Performance-9.81%-2.00%-1.84%-1.32%1 Month Performance-21.49%-7.47%-3.65%0.60%1 Year Performance-3.06%31.80%31.64%26.23% Relmada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLMDRelmada Therapeutics4.0882 of 5 stars$2.85-4.4%$7.50+163.2%-3.4%$85.98MN/A-0.9910NLTXNeoleukin TherapeuticsN/A$15.33-11.0%N/A+30.5%$144.07MN/A-4.9390High Trading VolumeZIOPZIOPHARM OncologyN/AN/AN/AN/A$187.12MN/A-2.01105Analyst ForecastKMDAKamada3.8063 of 5 stars$5.86+0.7%$14.50+147.4%+23.3%$336.83M$142.52M20.79360Analyst RevisionQTTBQ32 Bio1.6142 of 5 stars$27.28-6.2%$72.33+165.2%N/A$332.27M$1.16M0.0039CYRXCryoport2.8991 of 5 stars$6.57-5.2%$12.50+90.3%-52.6%$324.76M$233.26M-1.941,170Insider TradeBTMDbiote3.1975 of 5 stars$5.96-2.1%$8.39+40.7%+19.8%$323.15M$185.36M23.31194ACIUAC Immune2.2991 of 5 stars$3.24-0.9%$12.00+270.4%+0.0%$320.57M$16.48M0.00140Positive NewsCMPSCOMPASS Pathways2.8558 of 5 stars$4.61-1.1%$30.67+565.2%-23.0%$315.42MN/A0.00120Short Interest ↓JSPRJasper Therapeutics2.6633 of 5 stars$20.98+1.4%$74.86+256.8%+227.3%$314.70MN/A0.0020SAGESage Therapeutics4.2697 of 5 stars$5.10+3.9%$12.89+152.7%-75.1%$311.97M$86.46M-0.88690Analyst ForecastNews CoverageGap Down Related Companies and Tools Related Companies Neoleukin Therapeutics Alternatives ZIOPHARM Oncology Alternatives Kamada Alternatives Q32 Bio Alternatives Cryoport Alternatives biote Alternatives AC Immune Alternatives COMPASS Pathways Alternatives Jasper Therapeutics Alternatives Sage Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RLMD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLMD Stock Alerts